Advice
following an abbreviated submission:
sumatriptan 85mg / naproxen 457mg (Suvexx®) is not recommended for use within NHSScotland.
Indication under review: the acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient.
Suvexx® offers a combination tablet of sumatriptan and naproxen. It is available at a considerable cost premium to sumatriptan 100mg and naproxen 500mg tablets taken separately.
Download detailed advice260KB (PDF)
Medicine details
- Medicine name:
- sumatriptan (Suvexx®)
- SMC ID:
- SMC2756
- Indication:
The acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient.
- Pharmaceutical company
- Orion Pharma (UK) Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Not recommended
- Date advice published
- 09 June 2025